US Patent 11866502 Anti-FGFR2 antibodies and methods of use thereof
Patent 11866502 was granted and assigned to Regeneron Pharmaceuticals on January, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 12 Jan, 2024
Golden AI
Edits made to:
Infobox (+21 properties)
Article (+438 characters)
US Patent 11866502 Anti-FGFR2 antibodies and methods of use thereof
Article
Patent abstract
Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Amy Han0
Christopher Daly0
Frank Delfino0
Li Zhang0
Thomas Nittoli0
Date of Patent
January 9, 2024
0Patent Application Number
175071380
Date Filed
October 21, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11866502 Anti-FGFR2 antibodies and methods of use thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.